Company intelligence / Profile preview

Stella Pharma

Ownership: Private
Development stage: Other

Overview

Stella Pharma has developed SPM‐011, a boron-containing small molecule drug used as part of boron neutron capture therapy (BNCT), an innovative radiotherapy for certain cancers. SPM‐011 has been approved in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The company continues to develop BNCT applications for additional indications such as malignant glioma, meningioma, melanoma, and angiosarcoma[3].

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceutical
Industry: Biotech

Drug pipeline

3 assets

borofalan

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Stella Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stella Pharma.

Explore the full profile